Literature DB >> 26110718

Covalent-Allosteric Kinase Inhibitors.

Jörn Weisner1, Rajesh Gontla1, Leandi van der Westhuizen2, Sebastian Oeck3, Julia Ketzer4,5, Petra Janning6, André Richters1, Thomas Mühlenberg4,5, Zhizhou Fang1, Abu Taher2, Verena Jendrossek3, Stephen C Pelly2, Sebastian Bauer4,5, Willem A L van Otterlo2, Daniel Rauh7.   

Abstract

Targeting and stabilizing distinct kinase conformations is an instrumental strategy for dissecting conformation-dependent signaling of protein kinases. Herein the structure-based design, synthesis, and evaluation of pleckstrin homology (PH) domain-dependent covalent-allosteric inhibitors (CAIs) of the kinase Akt is reported. These inhibitors bind covalently to a distinct cysteine of the kinase and thereby stabilize the inactive kinase conformation. These modulators exhibit high potency and selectivity, and represent an innovative approach for chemical biology and medicinal chemistry research.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; drug design; inter-domain interactions; medicinal chemistry; tumor thermapeutics

Mesh:

Substances:

Year:  2015        PMID: 26110718     DOI: 10.1002/anie.201502142

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  20 in total

1.  Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.

Authors:  Dries J H De Clercq; David E Heppner; Ciric To; Jaebong Jang; Eunyoung Park; Cai-Hong Yun; Mierzhati Mushajiang; Bo Hee Shin; Thomas W Gero; David A Scott; Pasi A Jänne; Michael J Eck; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2019-10-22       Impact factor: 4.345

2.  KRAS G12C fragment screening renders new binding pockets.

Authors:  Magali Mathieu; Valérie Steier; Florence Fassy; Cécile Delorme; David Papin; Bruno Genet; Francis Duffieux; Thomas Bertrand; Laure Delarbre; Hélène Le-Borgne; Annick Parent; Patrick Didier; Jean-Pierre Marquette; Maryse Lowinski; Jacques Houtmann; Annabelle Lamberton; Laurent Debussche; Rak Alexey
Journal:  Small GTPases       Date:  2021-09-24

3.  Spotlight on AKT: Current Therapeutic Challenges.

Authors:  Ina Landel; Lena Quambusch; Laura Depta; Daniel Rauh
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

4.  Spatial and temporal alterations in protein structure by EGF regulate cryptic cysteine oxidation.

Authors:  Jessica B Behring; Sjoerd van der Post; Arshag D Mooradian; Matthew J Egan; Maxwell I Zimmerman; Jenna L Clements; Gregory R Bowman; Jason M Held
Journal:  Sci Signal       Date:  2020-01-21       Impact factor: 8.192

5.  Meeting Proceedings ICBS2016-Translating the Power of Chemical Biology to Clinical Advances.

Authors:  Yugo Kuriki; Toru Komatsu; Peter D Ycas; Sara K Coulup; Erick J Carlson; William C K Pomerantz
Journal:  ACS Chem Biol       Date:  2017-03-17       Impact factor: 5.100

6.  Protein Labeling and Crosslinking by Covalent Aptamers.

Authors:  Yaniv Tivon; Gianna Falcone; Alexander Deiters
Journal:  Angew Chem Int Ed Engl       Date:  2021-06-09       Impact factor: 16.823

Review 7.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

Review 8.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

9.  Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK.

Authors:  Mike Bührmann; Bianca M Wiedemann; Matthias P Müller; Julia Hardick; Maria Ecke; Daniel Rauh
Journal:  PLoS One       Date:  2017-09-11       Impact factor: 3.240

10.  An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

Authors:  Daniel Zaidman; Paul Gehrtz; Mihajlo Filep; Daren Fearon; Ronen Gabizon; Alice Douangamath; Jaime Prilusky; Shirly Duberstein; Galit Cohen; C David Owen; Efrat Resnick; Claire Strain-Damerell; Petra Lukacik; Haim Barr; Martin A Walsh; Frank von Delft; Nir London
Journal:  Cell Chem Biol       Date:  2021-06-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.